Frankfurt
20.12.24
15:29 Uhr
1,686 Euro
+0,146
+9,48 %
+9,48 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Advicenne Finalizes Agreement with Primex Pharmaceuticals AG | 219 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 28.11. | Advicenne Announces its 2025 Financial Calendar | 53 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 01.10. | Advicenne achieves major milestones in the US thanks to several positive FDA opinions on ADV7103 | 319 | Business Wire | FDA agrees to submission of a marketing authorization application for ADV7103 in dRTA without further clinical studies. The positive orphan drug designation decision for ADV7103 in cystinuria... ► Artikel lesen | |
| 18.09. | Advicenne Reports Its First Half Financial Results as of June 30, 2024, and Updates on Its Activities | 315 | Business Wire | Sibnayal® gross sales up 28% to €1.25 million including royalties paid by commercial partners (16% excluding royalties) Continued progress towards current operating breakeven Cash... ► Artikel lesen | |
| ADVICENNE Aktie jetzt für 0€ handeln | |||||
| 18.07. | Advicenne Announces an 8.8% Increase in Gross Sales for H1 2024 and Provides an Update on Its Activities | 307 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 15.05. | Advicenne Announces the Approval of All Resolutions Supported by the Board of Directors at Its Combined General Meeting | 254 | Business Wire | Regulatory News:
The Combined General Meeting of shareholders of Advicenne (Euronext Growth Paris ALDVI FR0013296746) (Paris:ALDVI), a specialty pharmaceutical company dedicated to the development... ► Artikel lesen | |
| 28.03. | Advicenne: Strong improvement of 2023 results thanks to sustained commercial activity on Sibnayal | 471 | Business Wire | Sibnayal volume up 84%.
Gross sales exceed €4 million for the first time.
Sharp decrease in net loss to -7.03 M€ vs. -11.47 M€ in 2022.
Year-end cash position at €5.25 million... ► Artikel lesen | |
| 25.03. | Advicenne: FDA Grants Orphan Drug Designation to ADV7103 for the Treatment of Cystinuria. | 484 | Business Wire | After distal Renal Tubular Acidosis (dRTA) in December 2022, ADV7103 is granted "orphan drug" status in the United States in cystinuria. A long-awaited milestone for the Company and its flagship... ► Artikel lesen | |
| 23.01. | Advicenne Reports 2023 Gross Sales1 up 20% to €4.43 Million | 361 | Business Wire | PARIS--(BUSINESS WIRE)--Regulatory News:
Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative... ► Artikel lesen | |
| 28.12.23 | Advicenne Announces Its 2024 Financial Calendar | 483 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 25,300 | +0,06 % | Pfizer: Aktien-Favorit 2025? | Das Börsenjahr 2024 verlief für die Aktie des US-amerikanischen Pharmakonzerns Pfizer recht enttäuschend. Größtenteils stand Pfizer unter Abgabedruck. Der Glanz vergangener Jahre ist endgültig verblast.... ► Artikel lesen | |
| ABBVIE | 169,00 | +0,33 % | AbbVie: Schon wieder - nächste Übernahme | Der Pharma-Riese AbbVie stärkt sein Immunologie-Portfolio. Für einen dreistelligen Millionen-Dollar-Betrag sichern sich die Amerikaner die Dienste des Biotech-Unternehmens Nimble Therapeutics. Das Übernahmeziel... ► Artikel lesen | |
| HALEON | 4,643 | -0,24 % | Haleon plc - 6-K, Report of foreign issuer | ||
| LIGAND PHARMACEUTICALS | 109,00 | -0,91 % | Zacks Small Cap Has Strong Estimate for LGND FY2026 Earnings | ||
| ACHIEVE LIFE SCIENCES | 3,930 | +10,86 % | Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer | SEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization... ► Artikel lesen | |
| ROYALTY PHARMA | 23,670 | -1,13 % | Royalty Pharma-Aktie erreicht 52-Wochen-Tief bei 24,7 US-Dollar | ||
| TG THERAPEUTICS | 30,985 | +0,42 % | TG Therapeutics, Inc.: New Data for BRIUMVI (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment | During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained consistent... ► Artikel lesen | |
| EISAI | 25,630 | +0,63 % | Eisai's EA Pharma, Newron In Agreement For Evenamide In Japan And Other Asian Territories | TOKYO (dpa-AFX) - Newron Pharmaceuticals S.p.A. (NWRN) and EA Pharma Co., Ltd., a unit of Eisai Co., Ltd. (ESALF.PK), Friday announced that they have entered into a license agreement to develop... ► Artikel lesen | |
| DR REDDYS | 14,700 | +5,76 % | DR REDDYS LABORATORIES LTD - 6-K, Report of foreign issuer | ||
| INTRA-CELLULAR THERAPIES | 81,00 | +0,62 % | Intra-Cellular Therapies, Inc.: Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy | The sNDA submission is based on positive results from Studies 501 and 502 demonstrating CAPLYTA's robust antidepressant efficacy and favorable safety and tolerability profileCAPLYTA, if approved as... ► Artikel lesen | |
| VERONA PHARMA PLC ADR | 40,000 | -0,99 % | AKTIONÄR-Tipp Verona Pharma dreht schon wieder auf: Neues Rekordhoch! | Die Aktie von Verona Pharma gehört definitiv zu den positiven Überraschungen im Biopharma-Sektor im Jahr 2024. Seit der Zulassung der neuartigen COPD-Therapie Ohtuvayre (Ensifentrine) Ende Juni befindet... ► Artikel lesen | |
| BETTERLIFE PHARMA | 0,064 | -0,78 % | BetterLife Pharma Inc.: BetterLife Announces Favorable Outcome in New York Legal Claims | VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. ("BetterLife") (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development... ► Artikel lesen | |
| ENTOURAGE HEALTH | 0,011 | 0,00 % | Entourage Health Corp.: Entourage Health Reports Strong Third Quarter 2024 Financial Results | The Company achieved a total revenue of $13.6 million.Gross Profit Margins continue to demonstrate a solid performance with 30% growth year-over-year.SG&A achieves a significant reduction, reflecting... ► Artikel lesen | |
| KYOWA KIRIN | 14,700 | +0,68 % | Für bessere Therapien gegen Blutkrebs: Spin-off Cimeio arbeitet mit Pharmakonzern Kyowa Kirin zusammen | ||
| IGC PHARMA | 0,330 | -3,51 % | IGC Pharma, Inc.: IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 | POTOMAC, MD / ACCESSWIRE / December 19, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE American:IGC) today announced that the Company's management team will participate in BIO Partnering @ JPM... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADVICENNE finden Sie auf Wallstreet Online.
